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Diabetic Ketoacidosis: Pathophysiology and Treatment 
Diabetic ketoacidosis (DKA), also known as diabetic acidosis or diabetic coma, is a 
severe complication of diabetes mellitus (DM; Michel, 2011). More commonly seen in patients 
with type 1 diabetes (T1D), DKA results when lipid breakdown generates a surplus of acidic 
ketone bodies (Guven, Matfin, & Kuenzi, 2009). According to Dods (2013), DKA can be 
defined as a condition with “blood glucose greater than 250 mg/dL, blood bicarbonate less than 
15 mEq/L, pH less than 7.35, ketonemia, and increased anion gap” (p. 266). The 
pathophysiology of DKA in patients with T1D will first be addressed, followed by a discussion 
of proper emergency treatment for this life-threatening condition. 
 The three main abnormalities of DKA patients include hyperglycemia, ketosis, and 
metabolic acidosis (Guven et al., 2009). An episode of DKA is precipitated by insulin deficiency 
with hyperglycemia. Insulin deficiency may develop in a patient following illness or infection, 
an insufficient insulin dose, ignorance of the condition of T1D, neglect of the medication 
regimen, and defective self-health maintenance (Michel, 2011). When insulin fails to provide 
adequate glucose, the cells tap into the fat stores for fuel (Petit & Adamee, 2011). It is the acidic 
products of fat metabolism that account for the acidosis. Normally, pancreatic beta cells release a 
bolus of insulin in response to rising blood glucose levels; however, in T1D the beta cells are 
destroyed through autoimmune process and the result is an absolute insulin deficiency (Michel, 
2011). Without insulin secretion, hyperglycemia persists, and the cells starve for energy. 
 The energy-hungry cells stimulate adipose tissue lipolysis, releasing free fatty acids into 
the blood stream. Increased breakdown of adipose tissue into glycerol and fatty acids is related to 
the increased availability of tissue lipase, an enzyme that is suppressed by insulin. Low insulin 
levels also correlate with low lipoprotein lipase activity, which leads to lipolysis. Free fatty acids 
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circulate until they reach the liver and are transported into mitochondria for oxidation by 
carnitine palmitoyl transferase (CPT1). It is pertinent to note that CPT1 is usually inhibited when 
insulin levels are normal. Acetyl Coenzyme A (CoA) is an enzyme that responds to the presence 
of insulin by catalyzing the transformation of acetyl CoA into malonyl CoA. Malonyl CoA is the 
molecule that inhibits CPT1 and, therefore, fatty acid oxidation. When CPT1 is unhindered by 
insulin, it shuttles fatty acids into the hepatic mitochondria where they undergo oxidation and 
form ketone bodies, namely, beta-hydroxybutyrate, acetoacetate, and acetone (Casteels & 
Mathieu, 2003; Marieb, 2004).  
 Ketones can be used as an alternate fuel source by cells lacking mitochondria and by 
brain cells, but in a state of insulin deficiency ketone utilization by the peripheral tissues is 
diminished (Harvey, 2010; Casteels & Mathieu, 2003). An overproduction and an under-
utilization of ketoacids results in ketosis (Casteels & Mathieu, 2003). Bicarbonate ions buffer the 
increased hydrogen ions by forming water and carbon dioxide; nevertheless, as ketosis 
progresses bicarbonate cannot keep up, and a metabolic acidosis ensues (Casteels & Mathieu, 
2003). In a state of ketosis, beta-hydroxybutyrate and acetoacetate are eliminated by the kidneys 
along with their counter ions, potassium, and sodium (Dods, 2013). This ketonuria contributes to 
the acidosis by causing the hydrogen ion concentration to rise (2013). 
 Besides increased lipolysis, the body responds to the glucose-hungry cells by increasing 
serum glucose levels even though hypoglycemia is not the problem (Beard, 2011). 
Hyperglycemia is further exacerbated by the release of counter regulatory hormones (Casteels & 
Mathieu, 2003). Low insulin levels cause the secretion of hormones that increase hepatic 
formation of new glucose molecules and hepatic breakdown of stored glycogen into glucose 
molecules (Koul, 2009). Hormones such as glucagon, catecholamines, cortisol, and growth 
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hormone are released; they not only increase the blood glucose but also have an antagonistic 
effect toward insulin (Beard, 2011). Glucagon is a hormone secreted by the alpha cells of the 
islets of Langerhans that increases proteolysis, transports the resulting amino acids into liver 
cells, and converts these amino acids into glucose precursors during the process of 
gluconeogenesis (Guven et al., 2009). Insulin promotes the active transport of amino acids into 
the cells and prevents protein breakdown (Guven et al., 2009). Catacholamines respond to stress 
by stimulating lypolysis in adipose tissue, decreasing insulin secretion, and increasing hepatic 
glycogenolysis and gluconeogenesis (Michal, 2012). Corticotropin-releasing hormone is released 
from the hypothalamus and stimulates the pituitary gland to synthesize and secrete 
adrenocorticotropic hormone (ACTH), which induces the adrenal cortex to secrete cortisol into 
the blood (Michal, 2012). Cortisol acts as an antagonist to insulin by promoting gene 
transcription of catabolic enzymes in extrahepatic cells (Michal, 2010). Cortisol also stimulates 
gluconeogenesis in the liver (Michal, 2012). Growth hormone (GH) mobilizes fatty acids to be 
used as fuel and inhibits glucose uptake by insulin in the peripheral cells (Guven et al., 2009). 
With these in place, GH increases protein synthesis and sustains hyperglycemia (Guven et al., 
2009).  
 Patients with T1D exhibit polyuria and polydipsia. As the blood becomes increasingly 
overloaded with glucose, the kidneys’ reabsorbing threshold is surpassed and glucose is excreted 
in the urine. Glucose is an osmotically active particle and pulls water out of the filtrate and into 
the urine. Polydipsia occurs because hyperglycemia causes fluid shifts in the cells resulting in 
dehydration. T1D patients may also experience polyphagia because their cells are starving for 
energy and their body’s stores of carbohydrates, fats, and proteins are depleted. Because of this 
use of the body’s stores of fat and protein and the loss of fluid, patients with T1D often 
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experience weight loss. Polyphagia is not present in all T1D patients because of the epigastric 
pain and vomiting that often accompanies their acidotic state (Koul, 2009; Guven et al., 2009). 
 The osmotic diuresis that results in the patient’s experience of polyuria also has dramatic 
effects on electrolyte levels. Sodium, potassium, phosphate, and magnesium are lost in the urine 
which predisposes the DKA patient to dehydration and imbalanced electrolyte levels (Guven et 
al., 2009). Ketonemia leads to ketonuria; potassium and sodium are excreted with ketones as 
their counter ions (Dods, 2013). Despite the loss of potassium in the urine, potassium levels often 
stay normal due to potassium shifts from the intracellular compartment to the extracellular 
compartment (Grinslade & Buck, 1999). Circulating hydrogen ions move into the cells in an 
attempt to correct the acidosis (Casteels & Mathieu, 2003). Within the cells, the hydrogen 
cations are buffered and potassium cations leave the cell in order to maintain intracellular 
electrical balance (Casteels & Mathieu, 2003). Extracellular potassium may also be increased by 
proteolysis (Grinslade & Buck, 1999). Although the serum levels of potassium appear normal or 
even high, the total body potassium level is depleted in DKA patients (Casteels & Mathieu, 
2003).  
 A patient with DKA may take rapid, deep breaths called Kussmaul respirations in an 
attempt to blow off carbon dioxide to normalize the blood pH. According to Nattrass (2002), 
“Spontaneous decarboxylation of acetoacetate allows excretion of acetone through the lungs” (p. 
52), giving the breath a fruity odor. Tachycardia and hypotension may also manifest due  to 
decreased blood volume, which will be further depleted by vomiting (Guven et al., 2009; Koul, 
2009). 
 Proper treatment of DKA is focused on restoring blood volume, enhancing tissue 
perfusion, correcting hyperglycemia and acidosis, and normalizing electrolyte levels (Guven, 
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2009). Due to the emergent and life-threatening nature of DKA, the patient must be treated 
promptly. Intravenous (IV) access should be initiated to administer fluid and electrolyte 
replacement. Fluid replacement is necessary for expanding the blood volume so that the tissues 
can be perfused and receive insulin (Koul, 2009). Restored blood volume also diminishes the 
release of counter regulatory hormones especially catacholamines and cortisol (Casteels & 
Mathieu, 2003). When serum sodium is low, a solution of 0.9% NaCl should be infused at a rate 
of one liter per hour or at a rate that achieves a restored urine output of 30-60 mL/hr. and a 
stabilized blood pressure (Michel, 2011; Koul, 2009). If the sodium level is within or above the 
normal limits, 0.45% NaCl is used (Koul, 2009).  
 If fluid replacement dilutes the serum sodium concentration, cerebral edema may ensue 
especially in pediatric patients. DKA patients are often dehydrated before treatment because of 
the high concentration of osmotically active substances, such as glucose, in the extracellular 
fluid. According to Koul (2009), “Persistent glucose-induced hypertonicity is implicated in 
causing neural cells to produce osmotically active idiogenic molecules” (p. 140). Neural cells 
accumulate these molecules during dehydration to protect the brain from becoming too volume 
depleted. When IV fluids resolve the high serum osmolality, the brain cells draw water out of the 
extracellular fluid resulting in cerebral swelling. Monitoring for the manifestations of Cushing’s 
triad is useful for assessing increased intracranial pressure, and unequal pupil dilation may 
indicated herniation. Neurological assessments are key to identifying cerebral edema, and rapid 
intervention involves the administration of mannitol and an alteration of the IV fluid rate. If 
mannitol is not available, a hypertonic solution of three percent saline may be administered with 
careful observance of hypernatremia, hyperosmolality, and central pontine myelinolysis (Koul, 
2009).  
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 Because of the detrimental effects of cerebral edema, fluid replacement therapy should 
progress slowly. Since insulin draws potassium and glucose into the intracellular compartment, 
potassium levels should be ascertained before the administration of insulin to prevent 
hypokalemia. If the patient’s potassium level is low before fluid administration then potassium 
should be given along with fluid replacement. The potassium level should be restored to 3.5 to 
5.0 mg/dL to prevent cardiac dysrhythmias. Once the blood volume has been replenished and the 
potassium level is above 3.5 mg/dL, administration of insulin should begin (Michel, 2011). 
Insulin corrects hyperglycemia and hyperketonemia; a continuous IV infusion is initiated at a 
rate of 0.1 units/kg/hr. (Michel, 2011). The potassium level should be intensely monitored during 
insulin administration. Potassium should be added to the IV infusion if the level falls below 3.5 
mg/dL (Guven et al., 2009). The blood sugar should also be monitored during insulin therapy. If 
glucose levels reach 250 mg/dL a solution of five percent dextrose is administered to prevent 
hypoglycemia (Michel, 2011). Insulin should be infused slowly because rapidly lowering serum 
glucose levels may also precipitate cerebral swelling (Michel, 2011). According to Guven et al. 
(2009), severe acidosis exerts inhibitory effects on insulin. The patient should be started on a 
loading dose of regular insulin and then continuously infused with low doses of insulin (Guven 
et al., 2009).   
 DKA therapy must be actively guided by the fluid and electrolyte levels that the patient 
manifests. Koul (2009) encourages having two qualified medical personnel separately 
calculating fluid management to avoid calculation errors. Emergency supplies such as mannitol 
and dextrose solution should be readily available (Koul, 2009). Prevention of DKA is achieved 
through adequate patient teaching on the insulin regimen and early diagnosis of T1D in patients 
who may be at risk. 
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